| Literature DB >> 33520036 |
Oksana Horodnycha1, Andriy Zimenkovsky2.
Abstract
BACKGROUND: Antibiotic allergy is an important clinical and social-economical issue.Entities:
Keywords: Anti-Bacterial Agents; Drug Hypersensitivity; Fluoroquinolones; Hospitalization; Inappropriate Prescribing; Incidence; Macrolides; Medication Errors; Retrospective Studies; Ukraine; beta-Lactams
Year: 2021 PMID: 33520036 PMCID: PMC7819703 DOI: 10.18549/PharmPract.2021.1.2055
Source DB: PubMed Journal: Pharm Pract (Granada) ISSN: 1885-642X
Figure 1Algorithm summarizing the steps of the study
Characteristics of patients
Characteristics of patients
| Characteristics | All patients (n=101) (%) | Distribution of patients by years | |||
|---|---|---|---|---|---|
| 2015 (n=37) (%) | 2016 (n=36) (%) | 2017 (n=28) (%) | p-value | ||
| Gender | 0.2996 | ||||
| male | 22 (21.8) | 11 (29.7) | 7 (19.4) | 4 (14.3) | |
| female | 79 (78.2) | 26 (70.3) | 29 (80.6) | 24 (85.7) | |
| Age in years | 0.9415 | ||||
| mean (SD) | 48.5 (SD=17.0) | 48.1 (SD=16.2) | 47.9 (SD=15.9) | 49.7 (SD=19.7) | |
| min-max | 18–83 years | 18–76 years | 23–81 years | 20–83 years | |
| less than 20 | 1 (1.0) | 1 (2.7) | 0 | 0 | |
| 20-29 | 16 (15.8) | 5 (13.5) | 4 (11.1) | 7 (25.0) | |
| 30-39 | 18 (17.8) | 5 (13.5) | 9 (25.0) | 4 (14.3) | |
| 40-49 | 17 (16.8) | 8 (21.6) | 7 (19.4) | 2 (7.1) | |
| 50-59 | 22 (21.8) | 10 (27.0) | 8 (22.2) | 4 (14.3) | |
| 60-69 | 11 (10.9) | 2 (5.4) | 2 (5.6) | 7 (25.0) | |
| more than 69 | 16 (15.8) | 6 (16.2) | 6 (16.7) | 4 (14.3) | |
| Length of hospitalization, days | 0.1569 | ||||
| mean (SD) | 8.2 (SD=2.2) | 8.4 (SD=2.5) | 7.6 (SD=2.2) | 8.5 (SD=1.8) | |
| min-max | 2–13 days | 2–12 days | 2–11 days | 6–13 days | |
| 1-3 | 4 (4.0) | 2 (5.4) | 2 (5.6) | 0 | |
| 4-6 | 15 (14.8) | 6 (16.2) | 7 (19.4) | 2 (7.1) | |
| 7-9 | 54 (53.5) | 16 (43.2) | 20 (55.6) | 18 (64.3) | |
| 10-12 | 26 (25.7) | 13 (35.1) | 7 (19.4) | 6 (21.4) | |
| more than 12 | 2 (2.0) | 0 | 0 | 2 (7.1) | |
| Number of prescribed medications | 0.4125 | ||||
| mean (SD) | 5.4 (SD=1.2) | 5.3 (SD=1.8) | 5.2 (SD=1.4) | 5.6 (SD=1.3) | |
| min-max | 3–12 items | 3–12 items | 3–9 items | 4–9 items | |
|
Health status on admission
| |||||
| moderate-to-severe | 98 (97.0) | 36 (97.3) | 35 (97.2) | 27 (96.4) | |
| severe | 3 (3.0) | 1 (2.7) | 1 (2.8) | 1 (3.6) | |
| Health status on discharge | 0.2835 | ||||
| healthy | 70 (69.3) | 29 (78.4) | 24 (66.7) | 17 (60.7) | |
| improving | 31 (30.7) | 8 (21.6) | 12 (33.3) | 11 (39.3) | |
| Manifestation of allergic reaction | 0.0930 | ||||
| urticaria | 37 (36.6) | 14 (37.8) | 13 (36.1) | 10 (35.7) | |
| angioedema | 11(10.9) | 2 (5.4) | 8 (22.2) | 1 (3.6) | |
| urticaria w/angioedema | 53 (52.5) | 21 (56.8) | 15 (41.7) | 17 (60.7) | |
| Co-morbidities | 0.7419 | ||||
| yes | 31 (30.7) | 12 (32.4) | 12 (33.3) | 7 (25.0) | |
| no | 70 (69.3) | 25 (67.6) | 24 (66.7) | 21 (75.0) | |
| Previous drug allergy | 0.1610 | ||||
| yes | 36 (35.6) | 12 (32.4) | 17 (47.2) | 7 (25.0) | |
| no | 65 (64.4) | 25 (67.6) | 19 (52.8) | 21 (75.0) | |
SD standard deviation; urticaria w/angioedema urticaria with angioedema;
p-value was not determined
Antibiotics that led to allergic reactions and hospitalization in 2015, 2016 and 2017
| Antibiotics | All cases (n=101) | Distribution of cases by years n(%) | ||
|---|---|---|---|---|
| 2015 (n=37) | 2016 (n=36) | 2017 (n=28) | ||
| Penicillins | 34 (33.7) | 15 (40.5) | 9 (25.0) | 10 (35.7) |
| Cephalosporins | 15 (14.8) | 4 (10.8) | 3 (8.3) | 8 (28.6) |
| Fluoroquinolones | 14 (13.9) | 3 (8.1) | 7 (19.4) | 4 (14.3) |
| Macrolides | 8 (7.9) | 3 (8.1) | 3 (8.3) | 2 (7.1) |
| Chloramphenicol | 4 (3.9) | 2 (5.4) | 2 (5.6) | 0 |
| Sulfonamides | 3 (2.9) | 0 | 3 (8.3) | 0 |
| Lincosamides | 2 (1.9) | 1 (2.7) | 0 | 1 (3.6) |
| Tetracyclines | 1 (1.0) | 0 | 1 (2.8) | 0 |
| Pyridopyrimidines | 1 (1.0) | 0 | 1 (2.8) | 0 |
| 8-hydroxyquinoline derivatives | 1 (1.0) | 0 | 1 (2.8) | 0 |
| Nitrofuran derivatives | 1 (1.0) | 1 (2.7) | 0 | 0 |
| Antibiotics (names missed) | 17 (16.8) | 8 (21.6) | 6 (16.7) | 3 (10.7) |
Identified drug-related probelms in 2015, 2016 and 2017
| Items of DRPs | Distribution of DRPs by years; n (95%CI) | |||||
|---|---|---|---|---|---|---|
| 2015 (n=143) | 2016 (n=132) | 2017 (n=125) | ||||
| Inappropriate route of drug administration (n=100) | 37 | 25.9 (18.9:33.9) | 35 | 26.5 (19.2:34.9) | 28 | 22.4 (15.4:30.7) |
| Duplication of therapeutic group (n=94) | 33 | 23.1 (16.5:30.9) | 32 | 24.2 (17.2:32.5) | 29 | 23.2 (16.1:31.6) |
| Insufficient frequency of drug administration or insufficient daily dosage (n=76) | 22 | 15.4 (9.9:22.3) | 26 | 19.7 (13.3:27.5) | 28 | 22.4 (15.4:30.7) |
| Potential DDIs (n=64) | 26 | 18.2 (12.2:25.5) | 17 | 12.9 (7.7:19.8) | 21 | 16.8 (10.7:24.5) |
| Inappropriate drug (n=64) | 24 | 16.8 (11.1:23.9) | 21 | 15.9 (10.1:23.3) | 19 | 15.2 (9.4:22.7) |
|
| 0 | 0 | 1 | 0.8 (95%CI 0.0:4.2) | 0 | 0 |
|
| 1 | 0.6 (95%CI 0.0:3.8) | 0 | 0 | 0 | 0 |
SD standard deviation; DDIs drug-drug interactions; DRPs Drug-related problems; CI confidence interval;
P-level was not determined